Cullinan Associates Inc. Sells 1,241 Shares of Merck & Co., Inc. (NYSE:MRK)

Share on StockTwits

Cullinan Associates Inc. trimmed its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 1.1% in the fourth quarter, Holdings Channel.com reports. The firm owned 111,715 shares of the company’s stock after selling 1,241 shares during the quarter. Cullinan Associates Inc.’s holdings in Merck & Co., Inc. were worth $10,160,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Atwater Malick LLC bought a new position in shares of Merck & Co., Inc. during the 3rd quarter worth approximately $57,000. 1 North Wealth Services LLC bought a new position in shares of Merck & Co., Inc. during the 3rd quarter worth approximately $58,000. American National Bank bought a new position in shares of Merck & Co., Inc. during the 3rd quarter worth approximately $67,000. Lenox Wealth Management Inc. grew its stake in shares of Merck & Co., Inc. by 23.3% during the 3rd quarter. Lenox Wealth Management Inc. now owns 793 shares of the company’s stock worth $67,000 after acquiring an additional 150 shares in the last quarter. Finally, Balentine LLC grew its stake in shares of Merck & Co., Inc. by 58.4% during the 3rd quarter. Balentine LLC now owns 933 shares of the company’s stock worth $79,000 after acquiring an additional 344 shares in the last quarter. 74.50% of the stock is owned by institutional investors and hedge funds.

In other Merck & Co., Inc. news, EVP Julie L. Gerberding sold 102,073 shares of the firm’s stock in a transaction on Monday, January 13th. The stock was sold at an average price of $89.34, for a total transaction of $9,119,201.82. Following the completion of the sale, the executive vice president now owns 106,099 shares of the company’s stock, valued at approximately $9,478,884.66. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.27% of the company’s stock.

Several equities analysts have recently weighed in on the stock. ValuEngine cut shares of Merck & Co., Inc. from a “hold” rating to a “sell” rating in a research note on Tuesday. Morgan Stanley raised their price target on shares of Merck & Co., Inc. from $90.00 to $95.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 13th. Mizuho reaffirmed a “buy” rating and set a $100.00 price target on shares of Merck & Co., Inc. in a research note on Monday, January 6th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $95.00 price target on shares of Merck & Co., Inc. in a research note on Wednesday, January 8th. Finally, JPMorgan Chase & Co. set a $96.00 price target on shares of Merck & Co., Inc. and gave the stock a “buy” rating in a research note on Thursday, October 10th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and thirteen have issued a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $95.69.

NYSE:MRK opened at $91.54 on Thursday. The firm has a fifty day simple moving average of $89.80 and a 200 day simple moving average of $85.55. Merck & Co., Inc. has a 1-year low of $72.05 and a 1-year high of $92.64. The stock has a market capitalization of $228.96 billion, a PE ratio of 21.09, a P/E/G ratio of 1.80 and a beta of 0.52. The company has a current ratio of 1.26, a quick ratio of 0.98 and a debt-to-equity ratio of 0.84.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings results on Tuesday, October 29th. The company reported $1.51 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.24 by $0.27. Merck & Co., Inc. had a return on equity of 48.16% and a net margin of 20.26%. The business had revenue of $12.40 billion during the quarter, compared to the consensus estimate of $11.59 billion. During the same quarter last year, the firm posted $1.19 EPS. The company’s quarterly revenue was up 14.9% on a year-over-year basis. On average, equities analysts predict that Merck & Co., Inc. will post 5.15 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Wednesday, January 8th. Shareholders of record on Monday, December 16th were issued a dividend of $0.61 per share. This is an increase from Merck & Co., Inc.’s previous quarterly dividend of $0.55. The ex-dividend date was Friday, December 13th. This represents a $2.44 annualized dividend and a yield of 2.67%. Merck & Co., Inc.’s dividend payout ratio (DPR) is currently 56.22%.

Merck & Co., Inc. Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Read More: How Do You Calculate Return on Equity (ROE)?

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2020 BBNS.